CA
NZ
UK
AU
IND
US
…
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
This PINK-listed instrument appears to be a contingent value right tied to Ligand Pharmaceuticals that conveys a contractual claim to potential future cash payments if specified milestones are achieved. Payouts may depend on drug-development, licensing or settlement outcomes at the underlying company and could provide asymmetric upside for investors willing to accept speculative, event-driven exposure.
Primary risks include very limited market liquidity, high dependence on uncertain milestone outcomes and administrative or counterparty risk that could result in little or no payout.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 36.01M | 47.30M | -10.54M | 796.64M | 173.33M |
| Net income | -5.22M | 37.01M | -2.98M | 629.30M | 143.32M |
| Selling general administrative | 70.06M | 57.48M | 64.44M | - | - |
| Gross profit | 196.25M | 214.96M | 156.00M | -5.72M | 163.73M |
| Ebit | 37.81M | 78.89M | 25.84M | 832.38M | 221.61M |
| Ebitda | 89.36M | 28.56M | 31.99M | - | - |
| Depreciation and amortization | 51.55M | -50.34M | 6.14M | - | - |
| Non operating income net other | - | - | - | 25.31M | 57.88M |
| Operating income | 37.81M | 78.89M | 25.84M | 807.08M | 163.73M |
| Other operating expenses | 193.21M | 198.24M | 208.11M | 812.80M | - |
| Interest expense | 1.80M | -18.74M | 27.42M | 0.00M | 0.00M |
| Income tax expense | 41.23M | 10.29M | 7.55M | 167.34M | 30.01M |
| Total revenue | 196.25M | 277.13M | 186.42M | 120.28M | 251.45M |
| Total operating expenses | 193.21M | 136.06M | 177.69M | -812.80M | - |
| Cost of revenue | - | 62.18M | 30.42M | 126.00M | 87.73M |
| Total other income expense net | -1.80M | -31.60M | -36.38M | - | - |
| Net income from continuing ops | - | - | - | 629.30M | 143.32M |
| Net income applicable to common shares | - | - | - | 629.30M | 143.32M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 762.67M | 1301.38M | 1362.29M | 1494.91M | 1260.80M |
| Intangible assets | 342.45M | - | 595.33M | 230.54M | 251.25M |
| Other current assets | 3.40M | -330.24M | 6.04M | 63.07M | 89.19M |
| Total liab | 165.18M | 479.75M | 652.76M | 727.68M | 699.89M |
| Total stockholder equity | 597.49M | 821.63M | 709.52M | 767.23M | 560.91M |
| Deferred long term liab | - | - | - | 32.94M | - |
| Other current liab | 92.43M | 30.58M | 65.01M | 4.75M | 9.00M |
| Common stock | 0.02M | - | 0.02M | 0.02M | 0.02M |
| Retained earnings | 450.86M | - | 391.95M | 400.11M | -229.20M |
| Good will | 105.67M | - | 189.66M | 95.23M | 86.65M |
| Cash | 45.01M | 341.11M | 47.62M | 71.54M | 117.16M |
| Total current liabilities | 98.81M | 41.66M | 100.11M | 17.00M | 82.25M |
| Current deferred revenue | 0.35M | 11.00M | 29.43M | - | - |
| Net debt | 42.74M | 10.69M | -45.73M | - | - |
| Short term debt | 0.71M | 0.09M | 1.89M | - | 49.86M |
| Short long term debt total | 87.75M | 351.80M | 1.89M | - | - |
| Other stockholder equity | 147.59M | 821.63M | 318.36M | -0.22M | -1.02M |
| Property plant equipment | - | - | - | 7.18M | 5.37M |
| Total current assets | 263.60M | 464.75M | 500.56M | 1123.64M | 870.54M |
| Net tangible assets | - | - | - | 441.46M | 223.01M |
| Short term investments | 166.86M | 341.11M | 363.57M | 939.99M | 601.22M |
| Net receivables | 35.04M | 85.45M | 56.85M | 41.75M | 55.85M |
| Long term debt | - | - | - | 638.96M | 609.86M |
| Inventory | 13.29M | 27.33M | 26.49M | 7.30M | 7.12M |
| Accounts payable | 5.31M | - | 3.78M | 12.26M | 23.38M |
| Accumulated other comprehensive income | -0.98M | - | -0.80M | - | - |
| Common stock total equity | - | - | - | 0.02M | 0.02M |
| Retained earnings total equity | - | - | - | 400.11M | -229.20M |
| Non currrent assets other | 14.92M | 784.57M | 55.41M | 12.71M | 0.47M |
| Non current assets total | 499.07M | 836.63M | 861.73M | 25.61M | 46.52M |
| Long term debt total | - | - | - | 638.96M | 609.86M |
| Breakdown | 2022-12-31 | 2019-12-31 | 2018-12-31 | 2009-09-30 | 2008-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2019-12-31 | 2018-12-31 | 2009-09-30 | 2008-12-31 |
| Investments | - | -326.82M | -405.53M | - | - |
| Change to liabilities | - | -4.40M | -4.54M | - | - |
| Total cashflows from investing activities | - | 466.92M | -423.27M | - | - |
| Net borrowings | - | -27.32M | 515.40M | - | - |
| Total cash from financing activities | -275.99M | -485.17M | 328.58M | - | 12.31M |
| Net income | -33.36M | 629.30M | 143.32M | - | -42.31M |
| Change in cash | 25.48M | -47.59M | 99.38M | - | -1.54M |
| Begin period cash flow | 12.60M | - | - | 12.60M | 14.14M |
| End period cash flow | 38.08M | 12.60M | - | - | 12.60M |
| Total cash from operating activities | 137.85M | -29.34M | 194.06M | - | -33.07M |
| Depreciation | 51.55M | 38.08M | 53.22M | - | 2.07M |
| Other cashflows from investing activities | - | 796.29M | -16.86M | - | - |
| Change to inventory | 12.06M | -2.06M | -2.56M | - | - |
| Change to account receivables | 55.32M | - | - | - | - |
| Sale purchase of stock | - | -450.43M | -42.78M | - | - |
| Other cashflows from financing activities | -14.99M | -7.42M | -144.04M | - | 5.00M |
| Change to netincome | - | -717.87M | 9.08M | - | - |
| Capital expenditures | 17.92M | 2.55M | 0.89M | 0.00M | 0.53M |
| Change receivables | - | 25.46M | -29.54M | - | - |
| Cash flows other operating | - | 2.15M | 25.09M | - | - |
| Cash and cash equivalents changes | - | -47.59M | 99.38M | - | - |
| Change in working capital | 38.65M | - | - | - | 3.21M |
| Stock based compensation | 60.28M | - | - | - | 3.94M |
| Other non cash items | - | - | - | - | 0.48M |
| Free cash flow | 119.93M | - | - | - | -33.60M |
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| DOGEF Orsted A/S |
- -% |
19.75 | 28.82 | 0.66 | 6.50 | 0.07 | 3.88 | 15.58 |
| TBB AT&T Inc. 5.35% GLB NTS 66 |
0.11 0.62% |
17.75 | 4.60 | - | - | - | - | - |
| CCZ Comcast Holdings Corp |
- -% |
64.50 | 55.07 | - | - | - | - | - |
| STMZF Scottish Mortgage Investment Trust PLC |
-0.60 2.91% |
20.00 | - | - | 2.56 | - | - | - |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...